Julian Harrison, an analyst from BTIG, maintained the Buy rating on Abivax SA Sponsored ADR. The associated price target was raised to $112.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that highlight the promising outlook for Abivax SA. The company’s ABTECT trials have shown impressive results, particularly with the 50mg dose achieving significant clinical remission rates in ulcerative colitis, which surpassed expectations. This success is further supported by a strong safety profile, comparable to existing treatments like Entyvio, and the potential for broad commercial adoption due to its oral administration and novel mechanism of action.
Moreover, Abivax’s financial position is robust, with sufficient cash reserves to fund operations into late 2027, following a successful public offering. The company’s strategic plans include submitting regulatory applications in the latter half of 2026, contingent on forthcoming maintenance data. These elements, combined with the ongoing development of obefazimod for Crohn’s disease and other indications, underpin the optimistic Buy recommendation.
In another report released on September 1, LifeSci Capital also maintained a Buy rating on the stock with a $116.00 price target.